Neogenomics (NEO) Research & Development (2010 - 2026)

Neogenomics (NEO) has 17 years of Research & Development data on file, last reported at $27.3 million in Q2 2026.

• Quarterly Research & Development rose 13.29% year-over-year to $27.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $96.4 million (up 7.64% YoY) and the FY2025 annual result came in at $92.0 million, up 8.69% from the prior year.
• Research & Development advanced to $27.3 million in Q2 2026, from $23.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $27.3 million in Q2 2026 to a low of $16.3 million in Q1 2023.
• A 5-year average of $20.3 million and a median of $20.3 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development decreased 0.89% — and 2024, when it climbed 24.37%.
• Tracing NEO's Research & Development over 5 years: stood at $17.1 million in 2022, then rose by 5.43% to $18.1 million in 2023, then grew by 23.61% to $22.3 million in 2024, then climbed by 4.94% to $23.4 million in 2025, then increased by 16.35% to $27.3 million in 2026.
• The last three Research & Development figures came in at $27.3 million (Q2 2026), $23.8 million (Q1 2026), and $23.4 million (Q4 2025), per Business Quant data.